Copy Space. Empty Space SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has approved the at-home use of the flu vaccine spray FluMist, how do you know ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price target at p14,500.00. Sachin Jain’s rating is based on ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00. Etzer Darout has given his Buy rating due to a ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial. The Phase I trial, which had 72 participants, was ...

A fraud investigation linked to AstraZeneca (NASDAQ:AZN) has expanded to several government agencies, implicating dozens of senior executives at the company as of last week, Shanghai-based ...

LONDON, United Kingdom - AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...